STX - Shield Therapeutics' pricing will be key metric - Proactive Research Analyst
(NewsDirect)
Proactive Research Analyst Robin Davisonspeaks to Thomas Warner after publishing a new research note on irondefiency-focused commercial-stage specialty pharmaceutical companyShield Therapeutics.
Davison givesan overview of what readers can expect from the note, highlightingShield's recent half-year results and accompanying financingtransactions. The company's burgeoning relationship withcommercial partner Viatris is a key focus.
While the product's trajectory is promising, Davisonexplains that Shield has been grappling with the challenge of drugreimbursements in the US, leading to the incurring of some costs.However, plans are underway to assist doctors in navigating thissystem, with a view to securing a higher average drugprice.
Davison suggests that Shield's ability to increasethat average price will be a "key metric going forward." Heconcludes by saying that "the trajectory is going extremely well,[they' really just want to get the pricing issue sorted now and itshould be a great story." Davison's research note is availableon the Proactive website as is a interview with ShieldTherapeutics' CEO Greg Madison.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.